Imagine facing a life-threatening allergic reaction, even after taking precautions. That's the unsettling reality highlighted by a recent study focusing on anaphylaxis during CT scans with iodinated contrast. While rare, these reactions can be surprisingly severe and stubbornly resistant to treatment, demanding a re-think of how we approach patient safety in radiology.
A comprehensive analysis, published in the Annals of Allergy, Asthma & Immunology, examined over 700,000 CT scans involving iodinated contrast media (ICM). The overall incidence of anaphylaxis was found to be 0.02%, which translates to roughly 20 cases per 100,000 scans or about 48 cases for every 100,000 patients. Eduardo Saadi Neto, MD, and his team at the Mayo Clinic, meticulously reviewed these cases, uncovering some alarming trends.
Most reactions followed a typical pattern: symptoms appeared, the trigger (ICM) was removed, and appropriate treatment led to resolution. But here's where it gets controversial... a small but significant portion of cases defied this expected course. Approximately 3% of patients experienced biphasic reactions, where hypersensitivity symptoms returned without any further exposure to the contrast agent. These recurrences happened, on average, about 16.5 hours after the initial reaction and were all classified as anaphylaxis. Think of it as the allergic reaction coming back for an encore, even after the show seemed to be over.
And this is the part most people miss: Even more concerning were the 10% of patients who suffered from refractory anaphylaxis. These individuals required at least three doses of epinephrine or needed intravenous epinephrine, along with other symptom-directed medical interventions, to manage their reaction. Furthermore, 13% of the anaphylaxis cases were classified as life-threatening (Dribin Grade 5), occurring at a rate of approximately 2.7 cases per 100,000 scans. This underscores a critical point: while ICM-induced anaphylaxis is uncommon, a notable fraction of cases can be incredibly severe, emphasizing the need for swift recognition and treatment.
Tragically, one case of refractory anaphylaxis proved fatal, resulting in a mortality rate of 0.14 deaths per 100,000 scans. The patient had a history of contrast-induced urticaria (hives) but hadn't received the recommended premedication with steroids and antihistamines before the scan – a cautionary tale about the importance of adhering to preventative protocols, especially in patients with prior reactions. It's worth noting that this fatality rate is an improvement compared to studies from the 1990s, which reported rates of 0.21-0.39 per 100,000 scans. This improvement, the researchers suggest, may reflect the use of safer ICM agents and advancements in anaphylaxis management.
Interestingly, among the 35 patients with a prior history of reactions to contrast, 66% received prophylactic medication before their scans. The most common regimens included steroids alone (48%) or steroids with antihistamines (39%), while antihistamines alone were used in 13% of cases. In cases where patients weren't premedicated and subsequently experienced anaphylaxis, it was often because their previous reactions were deemed minor (e.g., itching or hives).
The study also revealed that substituting the ICM agent used in a previous reaction might be more effective than premedication in preventing recurrent allergic events. Premedication is generally not recommended when an ICM substitution is used. This brings up an important question: Are we relying too heavily on premedication when a simple change in contrast agent could be a safer, more effective strategy?
"Our findings underscore the unpredictable nature and potential severity of subsequent reactions to contrast, even among patients who receive premedication, and highlight the importance of careful risk assessment and adherence to evidence-based preventive strategies," the researchers emphasized.
The study, a retrospective single-center observational analysis, included 702,917 CT scans with ICM performed at the Mayo Clinic Hospital between January 2014 and November 2024. Researchers manually reviewed charts to identify anaphylaxis cases meeting established diagnostic criteria. Of the 143 patients diagnosed with anaphylaxis, the most frequently used ICM agents were iohexol (66%), iopromide (17%), and iodixanol (3%). It's noteworthy that 27% of patients experiencing reactions had no prior documented exposure to ICM, and 49% had previously tolerated ICM without any allergic symptoms. Most cases occurred in outpatient settings (69%), followed by emergency departments (28%), with a smaller number occurring in hospitalized patients.
Dr. Ronna Campbell, a co-author of the study, stressed the importance of preparedness: "Outpatient and imaging centers should have immediate access to epinephrine, the ability to start an infusion when needed, and clearly organized treatment kits. Because these reactions are rare, practice through simulations can make the difference in how effectively teams respond. The key to patient safety is rapid recognition and treatment, not reliance on premedication."
Surprisingly, the only significant predictor of severe anaphylaxis was older age (relative risk 1.13 per 5 years), with no significant association found with asthma or a history of medication allergies. This suggests that age-related physiological changes might play a role in the severity of these reactions.
Another critical finding was that only about half of the anaphylaxis patients received epinephrine, with lower adherence to this recommended treatment in outpatient settings. This could be due to variations in training, experience, and access to medications, as well as delayed or missed recognition of anaphylaxis, especially when initial symptoms are mild or atypical. This hesitation to administer epinephrine promptly can have serious consequences.
"These findings show that being ready to act quickly matters more than relying on premedication," Dr. Campbell stated, reinforcing the study's core message.
The study's limitations include the potential for missing milder biphasic reactions due to relatively short post-scan monitoring periods. Also, the single-center design might limit the generalizability of the findings, and the subjective nature of diagnostic classification could have introduced bias when distinguishing between physiological reactions and true anaphylaxis.
This research raises important questions about current protocols for managing potential anaphylactic reactions to iodinated contrast media. Are we adequately prepared for the possibility of severe, refractory reactions? Should we be prioritizing ICM substitution over premedication in certain cases? And how can we improve the recognition and treatment of anaphylaxis, particularly in outpatient settings? Share your thoughts and experiences in the comments below. Do you agree with the study's conclusions? What changes, if any, should be implemented in radiology departments to enhance patient safety?
